year CS as the Kaplan-Meier probability of surviving an additional 5 years (from diagnosis), given no OS event in the previous x years, adjusted for expected mortality by age and sex from U.S. life tables.

Results Median age was 60 years and 69% of patients were Caucasian. Relative 5-year survival was 41.3% overall, and decreased with increasing stage (71.2% for stage I vs. 26.0% for stage IV). CS did not improve with previous survival.

Conclusions Overall, survival rates were lower than those previously reported from Surveillance, Epidemiology, and End Results (SEER) data, and prognosis in ovarian cancer remains poor. Differences in estimates may reflect differing demographics, clinical characteristics, and treatment patterns. In contrast to prior studies, CS did not improve with time already survived. Our previous research in this sample suggests that time survived progression-free, specifically, may improve prognosis. Further research in diverse datasets is needed.

IGCS20_1398

372

SAFETY AND ACTIVITY OF THE ANTI-MESOTHELIN ANTIBODY-DRUG CONJUGATE ANETUMAB RAVTANSINE IN COMBINATION WITH PEGYLATED-LIPOSOMAL DOXORUBICIN IN PLATINUM-RESISTANT OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER

¹A Santin*, ²I Vergote, ³A Martín, ⁴K Moore, ⁵A Oaknin, ⁶I Romero, ⁷S Diab, ⁸LJ Copeland, ⁹B Monk, ¹⁰R Coleman, ¹¹TJ Herzog, ¹²J Siegel, ¹³A Walter, ¹⁴BH Childs, ¹⁵C Elbi, ¹⁶I Bulat. ¹Yale School of Medicine, USA; ²University Hospitals Leuven, Leuven Cancer Institute, Belgium; ³Clinica Universidad de Navarra, Spain; ⁴University of Oklahoma Health Sciences Center, USA; ⁵Vall d'Hebron Institute of Oncology, Spain; ⁶Instituto Valenciano De Oncología, Spain; ⁷Rocky Mountain Cancer Centers, USA; ⁸Ohio State University Medical Center, USA; ⁹Arizona Oncology, USA; ¹⁰McKesson Corporation, USA; ¹¹University of Cincinnati Cancer Institute, USA; ¹²Bayer HealthCare Pharmaceuticals, Inc., USA; ¹³Bayer AG, Germany; ¹⁴ARENIA Exploratory Medicine, Institute of Oncology Unit, Moldova

10.1136/ijgc-2020-IGCS.322

Introduction Treatment options for platinum-resistant ovarian cancer (PROC) remain a high medical need. Mesothelin is highly expressed in PROC. Anetumab ravtansine (ARv) is an antibody-drug conjugate that selectively targets mesothelin, consisting of a fully human anti-mesothelin monoclonal antibody conjugated to the cytotoxic maytansinoid tubulin inhibitor DM4.

Methods This phase Ib, open-label, dose-escalation (modified 3 +3 design, n=9) and expansion study (n=56) evaluated the safety/tolerability and clinical activity of ARv and pegylated liposomal doxorubicin (PLD, 30 mg/m² Q3W) in PROC. Mesothelin expression was assessed by central immunohistochemistry. Adverse events, tumor response (RECIST v1.1), and progression-free survival (PFS) were determined. Biomarker samples were assessed by ELISA, next-generation sequencing, and expression profiling.

Results ARv/PLD combination was safe and tolerated. No DLT was observed. MTD of ARv was 6.5 mg/kg Q3W. The most common ARv-related adverse events were nausea (38.5%), decreased appetite (30.8%), corneal disorder (29.2%), fatigue (29.2%), diarrhea (24.6%), and AST increase (21.5%).

In all measurable or evaluable patients (n=65), objective response rate (ORR) was 28% (95% CI 16.0–38.5%), including one complete and 17 partial responses with a median PFS

of 5.1 months. In an exploratory subset of patients (n=19) who received ≤3 prior lines of therapy with high mesothelin expression, the ORR was 42% with a median duration of response of 36 weeks. Median PFS was 8.5 months.

Conclusions/Implications These results established the RP2D, schedule, and mesothelin-positive target population of the ARv/PLD combination for the phase III study in PROC. Molecular profiling and correlation with observed clinical activity will be presented.

IGCS20_1399

373

PROTECTIVE ROLE OF CONIZATION BEFORE RADICAL HYSTERECTOMY IN EARLY-STAGE CERVICAL CANCER: A PROPENSITY-SCORE MATCHING STUDY

¹N Bizzarri*, ¹L Pedone Anchora, ²A Kucukmetin, ²N Ratnavelu, ²P Korompelis, ¹MV Carbone, ¹C Fedele, ¹M Bruno, ¹G Vizzielli, ¹V Gallotta, ¹R De Vincenzo, ³V Chiantera, ¹A Fagotti, ¹F Fanfani, ¹G Ferrandina, ¹G Scambia. ¹Fondazione Policlinico Universitario A. Gemelli, IRCCS, UOC Ginecologia Oncologica, Dipartimento per la salute della Donna e del Bambino e della Salute Pubblica, Italy; ²Northern Gynaecological Oncology Centre, Queen Elizabeth Hospital, UK

10.1136/ijgc-2020-IGCS.323

³Department of Gynecologic Oncology, ARNAS Ospedali Civico Di Cristina Benfratelli, University of Palermo, Italy

Introduction The aim of this study was to assess the prognostic role and the peri-operative outcomes of conization performed before radical hysterectomy in early-stage cervical carcinoma.

Abstract 373 Figure 1

Methods Multi-center retrospective observational cohort study including patients with FIGO 2009 IB1 cervical carcinoma treated with radical hysterectomy between 06/2004 and 06/2019. Patients were divided into two groups according to conization before radical surgery. One-to-one case-control matching was used to adjust the baseline characteristics.

Results 332 patients were included after propensity matching (166, 50% in each group) (table 1). 24/166 (14.4%) and 142/166 (85.6%) conization patients had negative and positive surgical margins on the conization specimen, respectively. No difference in intra- and post-operative complications was noted between the two groups ($p=0.542$ and $p=0.180$, respectively).

Abstract 373 Table 1 Comparison of characteristics of patients with or without conization before RH (after propensity match)
LVSI: lymph-vascular space involvement; RT: radiotherapy; CT: chemotherapy

Characteristic	Previous conization, N=166 Median, (% range)	No previous conization, N=166 Median (% range)	p-value
Age (years)	42 (24-77)	49 (25-82)	< 0.001
BMI (kg/m ²)	24.0 (16.9-33.8)	23.7 (18.3-36.0)	0.408
Radicality of hysterectomy (Querleu-Morrow)			0.523
A	5 (3.0)	6 (3.6)	
B	48 (28.9)	39 (23.5)	
C	113 (68.1)	121 (72.9)	
Surgical approach			< 0.001
Laparotomy	19 (11.4)	52 (31.3)	
Laparoscopy	129 (77.7)	80 (48.2)	
Robotic	18 (10.8)	34 (20.5)	
Any intra-operative complication	4 (2.4)	7 (4.2)	0.542
Post-operative complications			0.180
Grade 1-2	7 (4.3)	11 (6.6)	
Grade 3-5	3 (1.8)	8 (4.8)	
Histology			0.424
SCC	96 (57.8)	101 (60.8)	
Adenocarcinoma	59 (35.5)	50 (30.1)	
Adenosquamous	8 (4.8)	7 (4.2)	
Clear cell	0	3 (1.8)	
Undifferentiated	1 (0.6)	3 (1.8)	
Others	2 (1.2)	2 (1.2)	
Grade			0.030
1	11 (6.6)	14 (8.4)	
2	76 (45.8)	81 (48.8)	
3	28 (16.9)	62 (37.3)	
Unknown	51 (30.7)	9 (5.4)	
LVSI			1.000
Negative	103 (62.0)	103 (62.0)	
Positive	56 (33.7)	56 (33.7)	
Unknown	7 (4.3)	7 (4.3)	
Pathologic maximum tumor diameter (mm)	20 (8-40)	23 (6-40)	0.998
Pathologic maximum tumor diameter			0.272
≤ 20 mm	86 (51.8)	75 (45.2)	
> 20 mm	80 (48.2)	91 (54.8)	
Depth of stromal infiltration (mm)	6 (1-22)	8 (1-35)	< 0.001
Systematic pelvic lymphadenectomy	159 (95.8)	160 (96.4)	1.000
Number of removed pelvic lymph nodes	19 (0-67)	23.5 (0-78)	< 0.001
Metastatic pelvic lymph nodes (histology)	13 (7.8)	23 (13.9)	0.111
Positive surgical margins	0	1 (0.6)	1.000
Adjuvant treatment (RT or RT-CT)	46 (27.7)	68 (41.0)	0.015
Follow-up time (months)	40.5 (3-203)	37.5 (2-169)	0.978
Recurrences	14 (8.4)	31 (18.7)	0.010
Deaths	4 (2.4)	10 (6.0)	0.170

Patients undergoing conization before radical hysterectomy, received less adjuvant treatment ($p < 0.001$) and had a better 5-year disease-free survival (DFS) than patients who did not receive conization (89.8% versus 80.0%, respectively; $p = 0.010$) (figure 1). No difference in 5-year overall survival (OS) (97.1% versus 91.4%, respectively; $p = 0.114$) and in recurrence pattern ($p = 0.115$) was reported between the two groups. Factors significantly independently related to higher risk of recurrence were pathologic tumor diameter > 20 mm and no conization before radical hysterectomy ($p = 0.011$ and $p = 0.018$, respectively). The only independent variable influencing OS was pathologic tumor diameter > 20 mm ($p = 0.020$).

Conclusions Conization before radical hysterectomy was associated with improved DFS and lower probability of receiving adjuvant treatment in patients with FIGO-stage IB1 cervical cancer. No difference in peri-operative complications and OS was noted in these groups of patients.

IGCS20_1401

374 COMPARISON OF STAGE DISTRIBUTION AND OUTCOMES OF RADIOTHERAPY-TREATED CERVICAL CANCER BETWEEN THE INTERNATIONAL FEDERATION OF GYNECOLOGY AND OBSTETRICS 2009 AND 2018 STAGING SYSTEMS

K Tomizawa*, T Kaminuma, K Murata, D Irie, T Kumazawa, T Oike, T Ohno. *Department of Radiation Oncology, Gunma University Graduate School of Medicine, Japan*

10.1136/ijgc-2020-IGCS.324

Introduction Three-dimensional image-guided brachytherapy (3D-IGBT) has become widespread, improving the outcomes of cervical cancers dramatically. In 2018, the International Federation of Gynecology and Obstetrics (FIGO) staging system for cervical cancer was revised. However, the influence of the revisions on the stage distribution and outcomes of cervical cancers treated with 3D-IGBT remains unclear. To address this issue, we assembled a study cohort that comprised solely of cases treated with definitive radiotherapy using 3D-IGBT and compared the stage distribution and outcomes between the FIGO 2009 and FIGO 2018 staging systems.

Methods Patients with cervical squamous cell carcinoma treated with definitive radiotherapy using 3D-IGBT from 2009 through 2017 were retrospectively collected. The patients were stratified using the FIGO 2009 or 2018 criteria, and survival was analyzed by Kaplan-Meier methods.

Results In 221 patients (median follow-up, 60 months), stage migration occurred in 52.9% of the patients. Patients classified with the 2018 criteria as stage IIICr had the highest proportion (43.8%) of migration, and were mainly from the 2009 stages IIB and IIIB. The 2009 and 2018 schemas showed comparable performance at stratifying 5-year overall survival (OS) and 5-year progression-free survival (PFS) for patients in stages IB–IVA. The 2018 criteria effectively stratified 5-year OS and PFS in the stage III substages. The 5-year OS and PFS for stage IIIC1r patients varied according to tumor T stage.

Conclusion These results provide evidence for the utility of the revised 2018 FIGO staging system in the clinical management of cervical cancers in the 3D-IGBT era.

IGCS20_1402

375 THE CHANGING NATURE OF REFERRAL PATHWAYS FOR RISK REDUCING SALPINGO-OOPHORECTOMY IN A UK CANCER CENTRE

¹K Smallwood*, ¹A Phillips, ¹V Asher, ¹S Crockett, ²V Huang. ¹Royal Derby Hospital, UK; ²University of Nottingham, UK

10.1136/ijgc-2020-IGCS.325

Introduction In 2013 the National Institute of Clinical Excellence (NICE) released guidance changing the threshold for BRCA testing from a lifetime risk of 20% to 10%. In 2015 NHS England brought this change into practice. Previously the majority of women were referred based on family history alone. This study will demonstrate how this evidence has changed when and how women are referred for risk management in our hospital.

Methods A retrospective study of 274 patients referred to the family history clinic for consideration of risk reducing surgery between January 2009 and December 2018 at the Royal Derby Hospital.

Results The number of referrals made in 2013 and 2014 were double those made in 2012 however this trend did not continue. Prior to 2015 69% of referrals were based on family history alone, compared to 34% after 2015. In 2018 all women undergoing risk reducing surgery had a genetic diagnosis, compared to 30% in 2009. Median age at surgery has reduced from 50 in 2009, to 43 in 2018.

Conclusion There has been no significant increase in referrals despite a lower threshold for BRCA testing. Women not previously eligible for testing were still offered surgery based on family history alone. Genetic diagnosis has allowed more accurate risk assessment and enables us to counsel women appropriately. Salpingo-oophorectomy reduces ovarian cancer risk from up to 50% to around 1%. Women are now being diagnosed with the BRCA gene at a younger age which is reflected in the fall in median age at surgery.

IGCS20_1404

377 SENTINEL LYMPH NODE DETECTION IN ENDOMETRIAL CANCER: LAPAROSCOPIC VERSUS ROBOTIC APPROACH

N Bizzarri*, S Restaino, S Gueli Alletti, G Monterossi, A Gioè, E La Fera, V Gallotta, A Fagotti, G Scambia, F Fanfani. *Fondazione Policlinico Universitario A. Gemelli, IRCCS, UOC Ginecologia Oncologica, Dipartimento per la salute della Donna e del Bambino e della Salute Pubblica, Italy*

10.1136/ijgc-2020-IGCS.326

Introduction Sentinel lymph node (SLN) mapping with indocyanine green (ICG) is widely utilized in the staging process for apparent uterine-confined endometrial cancer. The aims of the present study were to assess bilateral SLN mapping with laparoscopic versus robotic approach, to assess variables affecting bilateral detection rate and to assess survival difference in patients with no/unilateral, compared to bilateral SLN detection.

Methods All patients diagnosed with endometrial cancer FIGO stage IA-IVB, treated with minimally-invasive primary surgery